Company Overview of Solasia Pharma K.K.
Solasia Pharma K.K. engages in developing, marketing, and importing/exporting oncology products. It focuses on developing and commercializing assets in the oncology/hematology fields. The company also provides SP-01 Sancuso, a transdermal system that delivers the anti-emetic and granisetron into the patient’s bloodstream who cannot swallow medicines due to nausea or mucositis; and SP-02 Darinaparsin, a mitochondrial-targeted agent (organic arsenic) for the treatment of various hematologic and solid cancers. It serves customers in Japan, China, Hong Kong, Macau, Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, the Philippines, Thailand, and internationally. Solasia Pharm...
Founded in 2006
Key Executives for Solasia Pharma K.K.
President and Representative Director
Acting Chief Financial Officer
Vice President of Corporate Development
Compensation as of Fiscal Year 2014.
Solasia Pharma K.K. Key Developments
Solasia Pharma KK Announces Management Changes; Receives Clinical Trial Permit from China SFDA for SP-01
Feb 6 13
Solasia Pharma KK announced a change in its executive leadership team. Yoshihiro Arai, currently General Manager and Head of Development of Solasia Pharma K.K., has been promoted to President and Representative Director of the company. Current Chief Executive Officer Steve Engen has announced his departure to pursue a new career opportunity. Mr. Arai joined Solasia Pharma K.K. in September 2007 with responsibility for all product development including clinical development and regulatory affairs. In order to progress clinical development in China, the company has established operations in Beijing and has hired core development and regulatory affairs staff. Furthermore, Ms. Vivian Zhang has joined the company as Solasia China General Manager and will be based in Shanghai. Vivian will build the Solasia China sales and marketing team, and prepare Sancuso(R) for China commercialization. Vivian joins Solasia after a career in marketing and sales at Shanghai Roche where she was responsible for Avastin(R) and Tarceva(R), two key oncology products for Roche in China.
The company also announced receipt of the Clinical Trial Permit (CTP) from the China SFDA for SP-01 (brand name: Sancuso(R)), the company's product for the treatment of chemotherapy-induced nausea and vomiting. Having received the CTP, the company said it is now preparing to initiate the required pivotal studies, and expects to file a New Drug Application (NDA) in China in the fourth quarter of 2013.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries